Lung cancer with dual EGFR and ALK driver alterations at baseline: a retrospective observational cohort study

References

• Rajendra A, Noronha V, Joshi A, et al. Epidermal growth factor receptor-mutated non-small-cell lung cancer: a primer on contemporary management. Cancer Res Stat Treat. 2019;2(1):36–53.
   Google Scholar
• Prabhash K, Vora A, Limaye S, et al. Treatment of advanced non-small-cell lung cancer: First line, maintenance, and second line– Indian consensus statement update (under the aegis of Lung Cancer Consortium Asia, Indian Cooperative Oncology Network, Indian Society of Medical and Pediatric Oncology, Molecular Oncology Society, and Association of Physicians of India). Cancer Res Stat Treat. 2021;4(2):279–314.
   Google Scholar
• Talreja VT, Noronha V, Joshi A, et al. Coexistence of epidermal growth factor receptor mutation and anaplastic lymphoma kinase translocation in non-small cell lung cancer: do we know the treatment sequence? Cancer Res Stat Treat. 2019;2(1):119–120.
   Google Scholar
• Sweis RF, Thomas S, Bank B, et al. Concurrent EGFR mutation and ALK translocation in non-small cell lung cancer. Cureus. 2016;8(2):e513.
   PubMedGoogle Scholar
• Lou NN, Zhang XC, Chen HJ, et al. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations. Oncotarget. 2016;7(40):65185–65195.
   PubMedGoogle Scholar
• Shin HJ, Kho BG, Kim MS, et al. Co-alteration of EGFR mutation and ALK rearrangement in non-small cell lung cancer: case series. Medicine (Baltimore). 2019;98(9):e14699.
   PubMed Web of Science ®Google Scholar
• Lo Russo G, Imbimbo M, Corrao G, et al. Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases. Oncotarget. 2017;8(35):59889–59900.
   PubMedGoogle Scholar
• Liu J, Mu Z, Liu L, et al. Frequency, clinical features and differential response to therapy of concurrent ALK/EGFR alterations in Chinese lung cancer patients. DDDT. 2019;13:1809–1817.
   PubMed Web of Science ®Google Scholar
• Behel V, Noronha V, Patil V, et al. Molecular tumor board–guided treatment of non-small-cell lung cancer with dual driver (ALK and EGFR) alterations. Cancer Res Stat Treat. 2022;5(2):312–316.
   Google Scholar
• Akl EA, Briel M, You JJ, et al. Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review. BMJ. 2012;344:e2809.
   PubMed Web of Science ®Google Scholar
• Chakraborty S. A step-wise guide to performing survival analysis. Cancer Res Stat Treat. 2018;1(1):41–45.
   Google Scholar
• Dessai S, Simha V, Patil V. Stepwise cox regression analysis in SPSS. Cancer Res Stat Treat. 2018;1(2):167–170.
   Google Scholar
• Dessai S, Patil V. Testing and interpreting assumptions of COX regression analysis. Cancer Res Stat Treat. 2019;2(1):108–111.
   Google Scholar
• Pao W, Hutchinson KE. Chipping away at the lung cancer genome. Nat Med. 2012;18(3):349–351.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wang S, Yang Z, et al. Co-occurring potentially actionable oncogenic drivers in non-small cell lung cancer. Front Oncol. 2021;11:665484.
   PubMed Web of Science ®Google Scholar
• Patil VM, Noronha V, Joshi A, et al. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma. ESMO Open. 2017;2(1):e000168.
   PubMed Web of Science ®Google Scholar
• Noronha V, Patil VM, Joshi A, et al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J Clin Oncol. 2020;38(2):124–136.
   PubMed Web of Science ®Google Scholar
• Bondili SK, Nandhana R, Noronha V, et al. Resistance mechanisms to epidermal growth factor receptor inhibitors in non-small cell lung cancer. Cancer Res Stat Treat. 2020;3(4):801–807.
   Google Scholar
• Kapoor A, Noronha V, Shetty O, et al. Molecular tumor board: case 2 – evolution of resistance in anaplastic lymphoma kinase driven non-small-cell lung carcinoma. Cancer Res Stat Treat. 2020;3(1):89–92.
   Google Scholar
• Zanwar S, Noronha V, Joshi A, et al. Efficacy of crizotinib in ALK mutant non-small cell lung cancers that are positive by IHC but negative by FISH compared to FISH positive cases. Indian J Cancer. 2017;54(4):678–680.
   PubMed Web of Science ®Google Scholar
• Noronha V, Ramaswamy A, Patil VM, et al. ALK positive lung cancer: clinical profile, practice and outcomes in a developing country. PLoS ONE. 2016;11(9):e0160752.
   PubMed Web of Science ®Google Scholar
• Pandey A, Rani M, Chandra N, et al. Impact of the coronavirus disease 2019 pandemic on cancer care delivery: a single-center retrospective study. Cancer Res Stat Treat. 2020;3(4):683–691.
   Google Scholar
• Pande P, Sharma P, Goyal D, et al. COVID-19: a review of the ongoing pandemic. Cancer Res Stat Treat. 2020;3(2):221–232.
   Google Scholar
• Noronha V, Shah D, Mokal S, et al. Deviation from standard cancer treatment during the first wave of the COVID-19 pandemic in India: a cross-sectional study. Cancer Res Stat Treat. 2022;5(2):212–219.
   Google Scholar
• Dettori JR. Loss to follow-up. Evid Based Spine Care J. 2011;2(1):7–10.
   Google Scholar